Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ademetionine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : MSI Methylation Sciences Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
Details : Ademethionine is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 10, 2020
Lead Product(s) : Ademetionine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : MSI Methylation Sciences Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Tetra BioPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers
Details : PPP001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Tetra BioPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
